Cannabinoids in the treatment of cancer

Cancer Lett. 2009 Nov 18;285(1):6-12. doi: 10.1016/j.canlet.2009.04.005. Epub 2009 May 12.

Abstract

Cannabinoids, the active components of the hemp plant Cannabis sativa, along with their endogenous counterparts and synthetic derivatives, have elicited anti-cancer effects in many different in vitro and in vivo models of cancer. While the various cannabinoids have been examined in a variety of cancer models, recent studies have focused on the role of cannabinoid receptor agonists (both CB(1) and CB(2)) in the treatment of estrogen receptor-negative breast cancer. This review will summarize the anti-cancer properties of the cannabinoids, discuss their potential mechanisms of action, as well as explore controversies surrounding the results.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents, Phytogenic / pharmacology*
  • Antineoplastic Agents, Phytogenic / therapeutic use
  • Benzoxazines / pharmacology
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / metabolism
  • Cannabinoids / pharmacology*
  • Cannabinoids / therapeutic use
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Female
  • Humans
  • Male
  • Morpholines / pharmacology
  • Naphthalenes / pharmacology
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • Neoplasms / pathology
  • Receptor, Cannabinoid, CB1 / agonists
  • Receptor, Cannabinoid, CB1 / metabolism
  • Receptor, Cannabinoid, CB2 / agonists
  • Receptor, Cannabinoid, CB2 / metabolism
  • Receptors, Estrogen / analysis
  • Signal Transduction / drug effects

Substances

  • Antineoplastic Agents, Phytogenic
  • Benzoxazines
  • Cannabinoids
  • Morpholines
  • Naphthalenes
  • Receptor, Cannabinoid, CB1
  • Receptor, Cannabinoid, CB2
  • Receptors, Estrogen
  • Win 55212-2
  • 1,1-dimethylbutyl-1-deoxy-Delta(9)-THC